Cargando…

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

OBJECTIVES: TP53 mutation is found frequently in therapy related acute myeloid leukemia (AML)/ myelodysplastic syndrome (MDS), AML and MDS patients with monosomy or complex karyotype. However, the prevalence and treatment outcome in TP53 mutated AML/MDS patients in Asian population are scarce. We th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niparuck, Pimjai, Police, Pornnapa, Noikongdee, Phichchapha, Siriputtanapong, Kanchana, Limsuwanachot, Nittaya, Rerkamnuaychoke, Budsaba, Chuncharunee, Suporn, Siriboonpiputtana, Teerapong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557522/ https://www.ncbi.nlm.nih.gov/pubmed/34717674 http://dx.doi.org/10.1186/s13000-021-01162-8

Ejemplares similares

Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand
por: Limsuwanachot, Nittaya, et al.
Publicado: (2020)

Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
por: Sirirat, Tanasan, et al.
Publicado: (2017)

The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome
por: Rujirachaivej, Punchita, et al.
Publicado: (2018)

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Singdong, Roongrudee, et al.
Publicado: (2016)

A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia
por: Limsuwanachot, Nittaya, et al.
Publicado: (2023)

Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
por: Niparuck, Pimjai, et al.
Publicado: (2019)

Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais
por: Noikongdee, Phichchapha, et al.
Publicado: (2021)

Incidence of anti-platelet factor4/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais
por: Boonyawat, Kochawan, et al.
Publicado: (2023)

Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14)
por: Kamseng, Parin, et al.
Publicado: (2021)

The Utilization of Karyotyping, iFISH, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple Myeloma
por: Sommaluan, Suchada, et al.
Publicado: (2017)

Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand
por: Niparuck, Pimjai, et al.
Publicado: (2010)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Treatment outcome and prognostic factors in PCNSL
por: Niparuck, Pimjai, et al.
Publicado: (2019)

Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL
por: Rungwittayatiwat, Sirapat, et al.
Publicado: (2021)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
por: Cumbo, Cosimo, et al.
Publicado: (2020)

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
por: Patel, Shyam A., et al.
Publicado: (2022)

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Loschi, Michael, et al.
Publicado: (2022)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Establishment of Dose-response Curves for Dicentrics and Premature Chromosome Condensation for Radiological Emergency Preparedness in Thailand
por: Rungsimaphorn, Benchawan, et al.
Publicado: (2016)

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022)

Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series
por: Chitasombat, Maria N., et al.
Publicado: (2018)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes
por: Wang, Wei, et al.
Publicado: (2021)

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
por: Ok, Chi Young, et al.
Publicado: (2015)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
por: Patel, Shyam A., et al.
Publicado: (2023)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

Intrauterine Growth Retardation Fetus with Trisomy 16 Mosaicism
por: Chareonsirisuthigul, Takol, et al.
Publicado: (2014)

Incidence and Types of Fetal Chromosomal Abnormalities in First Trimester of Thai Pregnant Women between Miscarriages and Intrauterine Survivals
por: Parinayok, Rachanee, et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports
por: Duarte, Fernando Barroso, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cu3dq0gfdfph9gjgkfl2ibvuvn